Hyphens Pharma (SGX:1J5) subsidiary Hyphens Pharma entered into a marketing and distribution agreement with medac Gesellschaft für klinische Spezialpräparate for the exclusive rights to register and commercialize Metoject(r) in Singapore, Malaysia, the Philippines, and Vietnam.
Metoject(r) is a subcutaneous autoinjector pen used for the treatment of rheumatoid arthritis, according to a filing with the Singapore Exchange on Tuesday.
The pen is already commercialized in over 15 states in Europe, the US and Japan.
Shares of Hyphens Pharma were up nearly 2% in recent trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。